Sana Biotechnology, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven D. Harr
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 188 East Blaine Street Seattle WA United States of America 98102
- IPO Date
- Feb 4, 2021
- CIK
- 0001770121
- Website
- sana.com
- Similar Companies
- Business
- Sana Biotechnology, Inc. develops engineered cell therapies aimed at repairing or controlling genes in cells and replacing missing or damaged cells to treat diseases at their root causes. Its primary products and services include engineered cell medicines leveraging in vivo delivery platforms using lipid nanoparticles and adeno-associated viruses; ex vivo cell engineering platforms for modifying therapeutic cells outside the body; and a hypoimmune platform designed to enable donor cells to evade immune rejection, broadening allogeneic cell therapy applications. The company’s pipeline features candidates targeting oncology, diabetes (notably the SC451 program for type 1 diabetes), autoimmune diseases, and CNS disorders, with prominent programs like the in vivo CAR T platform and SC291 for lupus. Founded in 2018 and headquartered in Seattle, Washington, Sana operates additional sites in Cambridge, Massachusetts, South San Francisco, and Rochester. Recent strategic shifts include suspending less successful allogeneic CAR T programs to reallocate resources toward high-potential assets such as SC451 and the in vivo CAR T platform, reflecting a focused optimization of its therapeutic pipeline. Additionally, Sana completed a $75 million public offering in 2025 to bolster its financial position, while its operational emphasis remains on advancing cell engineering technologies through extensive research and development. Its recent financial results demonstrate progress by surpassing earnings expectations with improved cost management despite ongoing investment in R&D, positioning the company toward potential future profitability and growth. Sana continues to engage key investors through presentations at major healthcare conferences, highlighting its leadership in engineered cell medicines and commitment to transforming treatment options for complex diseases.
Company News
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Sana (SANA) Upgraded to Buy: Here's What You Should Know
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting